How many insider trades does FilingIQ track for KZIA?

FilingIQ tracks 9 Form 4 insider transactions for KZIA (KAZIA THERAPEUTICS LTD), covering filings from Jan 8, 2026 onwards. 2 of those were filed in the last 90 days.

Are KZIA insiders net buyers or net sellers?

Across the full Form 4 history for KZIA, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does KZIA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is KZIA in?

KAZIA THERAPEUTICS LTD (KZIA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $160.89M.

KZIA insider trading

NasdaqCM Healthcare

KAZIA THERAPEUTICS LTD — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 0%

Market cap

$160.89M

About KAZIA THERAPEUTICS LTD

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Company website: www.kaziatherapeutics.com

KZIA insider activity at a glance

FilingIQ has scored 9 insider transactions for KZIA since Jan 8, 2026. The most recent filing in our index is dated Jun 19, 2026.

Across the full history, 0 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live KZIA trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,099

UNITED THERAPEUTICS Corp

APLS 274

Apellis Pharmaceuticals, Inc.

KYMR 232

Kymera Therapeutics, Inc.

GH 194

Guardant Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for KZIA?: FilingIQ tracks 9 Form 4 insider transactions for KZIA (KAZIA THERAPEUTICS LTD), covering filings from Jan 8, 2026 onwards. 2 of those were filed in the last 90 days.
Are KZIA insiders net buyers or net sellers?: Across the full Form 4 history for KZIA, 0 transactions (0%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does KZIA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is KZIA in?: KAZIA THERAPEUTICS LTD (KZIA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $160.89M.

Methodology & sources

Every KZIA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.